ATE501250T1 - Mutantes follistatin-polypeptid - Google Patents

Mutantes follistatin-polypeptid

Info

Publication number: ATE501250T1
Authority: AT; Austria
Prior art keywords: cys; integer; activity; amino acid; follistatin
Prior art date: 2004-04-15

Application number

AT05734002T

Other languages

English (en)

Inventor

Kunihiro Tsuchida

Tatsuya Murakami

Original Assignee

Techno Network Shikoku Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-04-15

Filing date

2005-04-15

Publication date

2011-03-15

2005-04-15 Application filed by Techno Network Shikoku Co Ltd filed Critical Techno Network Shikoku Co Ltd

2011-03-15 Application granted granted Critical

2011-03-15 Publication of ATE501250T1 publication Critical patent/ATE501250T1/de

Links

102000016970 Follistatin Human genes 0.000 title abstract 4
108010014612 Follistatin Proteins 0.000 title abstract 4
229920001184 polypeptide Polymers 0.000 title abstract 2
102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
230000000694 effects Effects 0.000 abstract 4
102000005606 Activins Human genes 0.000 abstract 2
108010059616 Activins Proteins 0.000 abstract 2
102100039939 Growth/differentiation factor 8 Human genes 0.000 abstract 2
108010056852 Myostatin Proteins 0.000 abstract 2
239000000488 activin Substances 0.000 abstract 2
125000003275 alpha amino acid group Chemical group 0.000 abstract 2
230000002401 inhibitory effect Effects 0.000 abstract 2
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 1
125000000539 amino acid group Chemical group 0.000 abstract 1
235000018417 cysteine Nutrition 0.000 abstract 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Hematology (AREA)
Biochemistry (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Neurology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Endocrinology (AREA)
Psychology (AREA)
Virology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)

AT05734002T 2004-04-15 2005-04-15 Mutantes follistatin-polypeptid ATE501250T1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
JP2004120023		2004-04-15
JP2004355293A JP4688483B2 (ja)	2004-04-15	2004-12-08	フォリスタチン変異体ポリペプチド
PCT/JP2005/007662 WO2005100563A1 (ja)	2004-04-15	2005-04-15	フォリスタチン変異体ポリペプチド

Publications (1)

Publication Number	Publication Date
ATE501250T1 true ATE501250T1 (de)	2011-03-15

Family

ID=35150007

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT05734002T ATE501250T1 (de)	2004-04-15	2005-04-15	Mutantes follistatin-polypeptid

Country Status (10)

Country	Link
US (1)	US7867973B2 (de)
EP (1)	EP1748069B1 (de)
JP (1)	JP4688483B2 (de)
KR (1)	KR20070039483A (de)
CN (1)	CN1993463B (de)
AT (1)	ATE501250T1 (de)
AU (1)	AU2005233474B2 (de)
CA (1)	CA2562885A1 (de)
DE (1)	DE602005026796D1 (de)
WO (1)	WO2005100563A1 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8128933B2 (en)	2005-11-23	2012-03-06	Acceleron Pharma, Inc.	Method of promoting bone growth by an anti-activin B antibody
WO2008030367A2 (en) *	2006-09-01	2008-03-13	The General Hospital Corporation	Selective myostatin inhibitors
TW201940502A (zh)	2007-02-02	2019-10-16	美商艾瑟勒朗法瑪公司	衍生自ＡｃｔＲＩＩＢ的變體與其用途
CN107252486B (zh)	2008-06-26	2021-10-22	阿塞勒隆制药公司	激活素-actrii的拮抗剂及在提高红细胞水平中的用途
KR101871510B1 (ko)	2008-06-26	2018-06-26	악셀레론 파마 인코포레이티드	액티빈-ａｃｔｒｉｉａ 길항물질을 투약하는 방법 및 치료된 환자의 모니터링
US8216997B2 (en)	2008-08-14	2012-07-10	Acceleron Pharma, Inc.	Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
MX385318B (es)	2009-06-08	2025-03-18	Acceleron Pharma Inc	Metodos para aumentar adipocitos termogenicos.
US20110129469A1 (en)	2009-11-03	2011-06-02	Acceleron Pharma Inc.	Methods for treating fatty liver disease
EP2875359A4 (de)	2012-03-30	2015-08-19	Charles R Drew University Of Medicine And Science	Zusammensetzungen und verfahren zur behandlung oder prävention von stoffwechselsyndromerkrankungen
WO2014116981A1 (en)	2013-01-25	2014-07-31	Shire Human Genetic Therapies, Inc.	Follistatin in treating duchenne muscular dystrophy
US10010498B2 (en)	2014-06-04	2018-07-03	Acceleron Pharma Inc.	Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins
CN106795224B (zh)	2014-06-04	2021-05-18	阿塞勒隆制药公司	用促滤泡素抑制素多肽治疗病症的方法和组合物
JP2016131541A (ja) *	2015-01-20	2016-07-25	学校法人藤田学園	トランスジェニック非ヒト哺乳動物及びその用途
WO2016154601A1 (en)	2015-03-26	2016-09-29	Acceleron Pharma Inc.	Follistatin-related fusion proteins and uses thereof
JPWO2017141987A1 (ja) *	2016-02-19	2018-12-06	コニカミノルタ株式会社	実験動物検体を定量評価することを特徴とする、非臨床試験方法
JP2021515576A (ja) *	2018-03-16	2021-06-24	イミュソフトコーポレーション	フォリスタチンを分泌するように遺伝子操作されたｂ細胞ならびにフォリスタチン関連疾患、状態、障害を処置するために、ならびに筋肉の成長および強度を増強するためにこれを使用する方法
US12522647B2 (en)	2019-01-22	2026-01-13	Paul Scherrer Institut	Beta-arrestin mutants
US12202869B2 (en) *	2019-03-01	2025-01-21	Knc Laboratories Co., Ltd.	Inhibition of myostatin signal by myostatin splice variant-derived protein and utilization thereof
CA3094859A1 (en) *	2020-10-01	2022-04-01	Entos Pharmaceuticals Inc.	Proteolipid vesicles formulated with fusion associated small transmembrane proteins
TW202530250A (zh) *	2024-01-25	2025-08-01	大陸商四川至善唯新生物科技有限公司	編碼卵泡抑素的核酸及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5182375A (en) *	1987-08-28	1993-01-26	The Salk Institute For Biological Studies	DNA encoding follistatin
ES2201076T3 (es) *	1993-03-19	2004-03-16	The Johns Hopkins University School Of Medicine	Factor-8 de diferenciacion del crecimiento.
US5545616A (en) *	1994-09-22	1996-08-13	Genentech, Inc.	Method for predicting and/or preventing preterm labor
US6656475B1 (en)	1997-08-01	2003-12-02	The Johns Hopkins University School Of Medicine	Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same
US6891082B2 (en) *	1997-08-01	2005-05-10	The Johns Hopkins University School Of Medicine	Transgenic non-human animals expressing a truncated activintype II receptor
US6369201B1 (en)	1998-02-19	2002-04-09	Metamorphix International, Inc.	Myostatin multimers
US6004937A (en) *	1998-03-09	1999-12-21	Genetics Institute, Inc.	Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11]
EP1147413B1 (de)	1999-01-21	2006-04-05	Metamorphix, Inc.	Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen
KR100750695B1 (ko)	1999-07-20	2007-08-22	파멕사 에이/에스	Ｇｄｆ-8 활성을 하향-조절하는 방법
JP2003527099A (ja) *	1999-11-03	2003-09-16	ザイモジェネティクス，インコーポレイティド	フォリスタチン関連タンパク質ｚｆｓｔａ４
EP1250357A4 (de)	2000-01-18	2004-06-16	Ovita Ltd	Myostatin und dessen mimetika
GB0100762D0 (en)	2001-01-11	2001-02-21	Smithkline Beecham Plc	Novel use
US6852693B2 (en) *	2002-02-07	2005-02-08	Blm Group	Compositions and methods for promoting lipid mobilization in humans
PL375045A1 (en) *	2002-02-21	2005-11-14	Wyeth	Gasp1: a follistatin domain containing protein
JP5355053B2 (ja)	2008-09-19	2013-11-27	住友化学株式会社	有害生物防除用組成物及び有害生物の防除方法

2004
- 2004-12-08 JP JP2004355293A patent/JP4688483B2/ja not_active Expired - Fee Related
2005
- 2005-04-15 AT AT05734002T patent/ATE501250T1/de not_active IP Right Cessation
- 2005-04-15 CA CA002562885A patent/CA2562885A1/en not_active Abandoned
- 2005-04-15 CN CN2005800198613A patent/CN1993463B/zh not_active Expired - Fee Related
- 2005-04-15 EP EP05734002A patent/EP1748069B1/de not_active Expired - Lifetime
- 2005-04-15 KR KR1020067023962A patent/KR20070039483A/ko not_active Abandoned
- 2005-04-15 US US11/578,408 patent/US7867973B2/en not_active Expired - Fee Related
- 2005-04-15 DE DE602005026796T patent/DE602005026796D1/de not_active Expired - Lifetime
- 2005-04-15 AU AU2005233474A patent/AU2005233474B2/en not_active Ceased
- 2005-04-15 WO PCT/JP2005/007662 patent/WO2005100563A1/ja not_active Ceased

Also Published As

Publication number	Publication date
KR20070039483A (ko)	2007-04-12
EP1748069A1 (de)	2007-01-31
AU2005233474A1 (en)	2005-10-27
JP2005323584A (ja)	2005-11-24
CN1993463B (zh)	2012-10-03
JP4688483B2 (ja)	2011-05-25
CA2562885A1 (en)	2005-10-27
WO2005100563A1 (ja)	2005-10-27
DE602005026796D1 (de)	2011-04-21
US20080090755A1 (en)	2008-04-17
AU2005233474B2 (en)	2010-12-09
US7867973B2 (en)	2011-01-11
EP1748069B1 (de)	2011-03-09
EP1748069A4 (de)	2008-04-30
CN1993463A (zh)	2007-07-04

Legal Events

Date	Code	Title	Description
2011-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE501250T1 (de)	2011-03-15	Mutantes follistatin-polypeptid
IN2014CN02050A (de)	2015-05-29
MX2009005655A (es)	2009-10-21	Composiciones y usos de un polipeptido alfa-amilasa del bacilo de la especie 195.
TW200710209A (en)	2007-03-16	Polishing composition
NZ594457A (en)	2013-06-28	Compositions and methods for the delivery of oxygen
BR0211750A (pt)	2004-10-13	Agente antiviral
TW200621233A (en)	2006-07-01	HCV NS3-NS4A protease inhibition
EP1801206A4 (de)	2009-01-14	Verfahren zur herstellung von l-arginin, l-ornithin oder l-citrullin
TW200726842A (en)	2007-07-16	Mutant glucose dehydrogenase
PL1649023T3 (pl)	2009-01-30	Polipeptyd o podwyższonej aktywności deaminazy cytozyny
MX2008009493A (es)	2008-10-03	Peptido novedoso y uso del mismo.
WO2009047992A1 (ja)	2009-04-16	Ｕｄｐ－グルクロン酸転移酵素およびそれをコードするポリヌクレオチド
IL175319A0 (en)	2006-09-05	Novel phosphate-binding protein, pharmaceutical compositions containing same and use thereof
MX2007000334A (es)	2007-06-25	Polipeptido.
WO2007062526A8 (en)	2007-08-30	Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
PL1791858T3 (pl)	2010-09-30	Zmodyfikowane białko kapsydowe VP1 z parwowirusa B19
MY139016A (en)	2009-08-28	PYRAZOLOPYRIDINE DERIVATIVES AS INHIBITORS OF ß-ADRENERGIC RECEPTOR KINASE 1
MX2010004624A (es)	2010-05-24	Oligomeros de organofosfonato.
SE0003815D0 (sv)	2000-10-18	Struktur som motverkar biologisk påväxt i akvatisk miljö
IN2009DN06580A (de)	2015-07-24
WO2006103101A3 (en)	2007-02-01	MEANS FOR THE INHIBITION OF ANTI-β1-ADRENERGIC RECEPTOR ANTIBODIES
TW200720281A (en)	2007-06-01	A method of manufacturing an organic silicon compound that contains a methacryloxy group or an acryloxy group
PH12013502021A1 (en)	2015-12-14	Platelet aggregation inhibitor composition
WO2008107782A3 (en)	2008-11-13	Modified hydroxylase and its applications
MY143765A (en)	2011-07-15	Neuropeptides for aquatic organisms culture